Abstract | BACKGROUND: AIMS AND METHODS: We compared 135 patients following a prospective pTDM protocol aiming at an infliximab trough level (IFXTL) between 5 and 10 μg/ml with sequential measurements of Fc, with 108 patients from a retrospective group under conventional management. We evaluated the rates of Fc remission (<250 μg/g) and other clinical outcomes at 2-year of follow-up. RESULTS: pTDM associated with higher rates of Fc remission (69.6% vs. 50.0%; P = 0.002), and steroid-free clinical remission (78.4% vs. 55.2%, P = 0.028) with a trend for clinical remission (79.3% vs. 68.5%, P = 0.075). There was no difference in treatment discontinuation (P = 0.195), hospitalization (P = 0.156), and surgery (P = 0.110). Higher IFXTL associated with Fc remission at week 14 (6.59 vs. 2.96 μg/ml, P < 0.001), and at the end of follow-up (8.10 vs. 5.03 μg/ml, P = 0.001). In patients reaching Fc remission after week 14, IFXTL increased from week 14 to the end of follow-up (2.71 vs. 8.54 μg/ml, P < 0.001). Fc remission associated with higher rates of clinical (85.8% vs. 56.8% P < 0.001) and steroid-free clinical remission (86.9% vs. 50.0% P < 0.001), lower IFX discontinuation (8.8% vs. 36.8%, P < 0.001), and hospitalization (13.5% vs. 33.7%, P < 0.001), without significance for surgery (6.1% vs. 12.6%, P = 0.101). CONCLUSION: pTDM was more effective than conventional management in inducing Fc remission which was associated with improved outcomes.
|
Authors | Samuel Raimundo Fernandes, Juliana Serrazina, Inês Coelho Rodrigues, Sónia Bernardo, Ana Rita Gonçalves, Ana Valente, Cilénia Baldaia, Paula Moura Santos, Luís Araújo Correia, Rui Tato Marinho |
Journal | European journal of gastroenterology & hepatology
(Eur J Gastroenterol Hepatol)
Vol. 33
Issue 12
Pg. 1539-1546
(12 01 2021)
ISSN: 1473-5687 [Electronic] England |
PMID | 33731596
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Gastrointestinal Agents
- Leukocyte L1 Antigen Complex
|
Topics |
- Drug Monitoring
- Gastrointestinal Agents
(adverse effects)
- Humans
- Inflammatory Bowel Diseases
(diagnosis, drug therapy)
- Leukocyte L1 Antigen Complex
- Prospective Studies
- Retrospective Studies
|